Matthew Klein Sells 16,000 Shares of ClearPoint Neuro (NASDAQ:CLPT) Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Matthew Klein sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $11.59, for a total transaction of $185,440.00. Following the completion of the sale, the director owned 46,935 shares of the company’s stock, valued at approximately $543,976.65. This trade represents a 25.42% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

ClearPoint Neuro Stock Up 3.3%

ClearPoint Neuro stock traded up $0.38 during trading hours on Tuesday, hitting $11.82. The company had a trading volume of 506,316 shares, compared to its average volume of 714,398. The firm has a market capitalization of $354.48 million, a P/E ratio of -11.70 and a beta of 1.29. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88. The firm’s fifty day moving average is $10.55 and its 200-day moving average is $12.71. ClearPoint Neuro, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $30.10.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The company had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million. On average, research analysts forecast that ClearPoint Neuro, Inc. will post -1.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Stifel Nicolaus assumed coverage on shares of ClearPoint Neuro in a report on Friday, May 8th. They issued a “buy” rating and a $16.00 price target for the company. B. Riley Financial lifted their price target on shares of ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $18.00.

Institutional Trading of ClearPoint Neuro

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLPT. Caitong International Asset Management Co. Ltd acquired a new position in shares of ClearPoint Neuro in the fourth quarter valued at about $25,000. Huntington National Bank acquired a new stake in ClearPoint Neuro during the third quarter worth about $44,000. BNP Paribas Financial Markets grew its stake in ClearPoint Neuro by 2,435.2% during the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after buying an additional 2,143 shares in the last quarter. Russell Investments Group Ltd. increased its position in ClearPoint Neuro by 1,079.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after purchasing an additional 2,158 shares in the last quarter. Finally, Legal & General Group Plc bought a new position in ClearPoint Neuro in the 2nd quarter valued at approximately $35,000. 30.08% of the stock is owned by institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.